HealthQuill Pulmonary Disease
The European Medicines Agency has approved Sanofi S.A.’s Dupixent (dupilumab) therapy as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease, according to a company statement.
Drugs Health Pharma

EMA approves Sanofi’s treatment for obstructive pulmonary disease

The European Medicines Agency has approved Sanofi S.A.’s Dupixent (dupilumab) therapy as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary.

Read More
Lysolipid, a byproduct of the human immune response to viruses and bacteria, may be behind lung instability caused due a life-threatening illness— acute respiratory distress syndrome, researchers said.
Drugs Health Pharma

Excess lysolipids may be main reason for acute respiratory distress syndrome

HQ Team March 13, 2024: Lysolipid, a byproduct of the human immune response to viruses and bacteria, may be behind lung instability caused.

Read More
X